ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Follicular Lymphoma Management: What Is the New Order?

SOHO 2023 Eleventh Annual Meeting

B. Kahl

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

Christopher Flowers

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Summary of Recent Advances in Follicular Lymphoma

Louisville Hematology Highlights

S. Gaballa

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Total Health

J. Chandler, B. Randolph, M. Onciu

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Randomized …

Insights from 2023 ASCO® Annual Meeting

J. Westin